Last reviewed · How we verify
Alpharix® Tetra
Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously.
Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously. Used for Indication under investigation in Phase 3 (specific indication not publicly disclosed).
At a glance
| Generic name | Alpharix® Tetra |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease or Oncology |
| Phase | Phase 3 |
Mechanism of action
As an mRNA vaccine platform, Alpharix Tetra encodes antigens that are translated by host cells to trigger both CD8+ T-cell and antibody-mediated immune responses. The 'Tetra' designation suggests it targets four distinct antigens or disease variants, leveraging Moderna's modular mRNA technology to address multiple pathogens or tumor-associated antigens in a single therapeutic formulation.
Approved indications
- Indication under investigation in Phase 3 (specific indication not publicly disclosed)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Maternal Determinants of Immunity to Influenza (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alpharix® Tetra CI brief — competitive landscape report
- Alpharix® Tetra updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI